Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma

Eun Joo Kang, Yoon Ji Choi, Jung Seon Kim, Seung Tae Kim, Kyong Hwa Park, In Keun Choi, Sang Cheul Oh, Jae Hong Seo, Sang Won Shin, Jun Suk Kim, Yeul Hong Kim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aim: There is no further treatment option for metastatic colon patients who are refractory to standard chemotherapy and to whom novel biological agents are not available. We evaluated the outcomes of mitomycin-C, 5-fluorouracil (5-FU) and leucovorin in patients with metastatic colon cancer previously treated with oxaliplatin/5-FU/leucovorin and irinotecan/5-FU/leucovorin.Methods: We retrospectively analyzed 46 patients who had received mitomycin-C/5FU/leucovorin between March 2008 and December 2009. All patients had failed prior first-line and second-line therapy containing oxaliplatin, irinotecan, and 5-FU.Results: The median age of the patients was 57.0 years (range, 34.0-76.0) and their median Eastern Cooperative Oncology Group performance status was 1 (0-2). A complete or partial response was not observed in any patient and stable disease was observed in 19 patients (41.3%). The median duration of follow up was 29 weeks (range 8-87 weeks). Median progression-free survival was 10 weeks (95% CI 8-12) and median overall survival was 38 weeks (95% CI 32-44). Grade 3 and 4 hematological toxicities included neutropenia in five patients (10.8%) and thrombocytopenia in four patients (8.8%). Grade 3 or 4 non-hematologic toxicities included nausea and vomiting in two patients. There were no treatment-related deaths.Conclusion: The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients.

Original languageEnglish
Pages (from-to)286-291
Number of pages6
JournalAsia-Pacific Journal of Clinical Oncology
Volume6
Issue number4
DOIs
Publication statusPublished - 2010 Dec 1

Fingerprint

Salvage Therapy
Leucovorin
Mitomycin
Fluorouracil
Adenocarcinoma
irinotecan
oxaliplatin
Biological Factors
Neutropenia
Thrombocytopenia
Colonic Neoplasms
Nausea
Disease-Free Survival
Vomiting
Colorectal Neoplasms
Colon
Therapeutics

Keywords

  • 5-FU
  • Leucovorin
  • Mitomycin
  • Refractory colon cancer

ASJC Scopus subject areas

  • Oncology

Cite this

@article{4f5bc69c6eb442408596b41ca2936ddc,
title = "Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma",
abstract = "Aim: There is no further treatment option for metastatic colon patients who are refractory to standard chemotherapy and to whom novel biological agents are not available. We evaluated the outcomes of mitomycin-C, 5-fluorouracil (5-FU) and leucovorin in patients with metastatic colon cancer previously treated with oxaliplatin/5-FU/leucovorin and irinotecan/5-FU/leucovorin.Methods: We retrospectively analyzed 46 patients who had received mitomycin-C/5FU/leucovorin between March 2008 and December 2009. All patients had failed prior first-line and second-line therapy containing oxaliplatin, irinotecan, and 5-FU.Results: The median age of the patients was 57.0 years (range, 34.0-76.0) and their median Eastern Cooperative Oncology Group performance status was 1 (0-2). A complete or partial response was not observed in any patient and stable disease was observed in 19 patients (41.3{\%}). The median duration of follow up was 29 weeks (range 8-87 weeks). Median progression-free survival was 10 weeks (95{\%} CI 8-12) and median overall survival was 38 weeks (95{\%} CI 32-44). Grade 3 and 4 hematological toxicities included neutropenia in five patients (10.8{\%}) and thrombocytopenia in four patients (8.8{\%}). Grade 3 or 4 non-hematologic toxicities included nausea and vomiting in two patients. There were no treatment-related deaths.Conclusion: The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients.",
keywords = "5-FU, Leucovorin, Mitomycin, Refractory colon cancer",
author = "Kang, {Eun Joo} and Choi, {Yoon Ji} and Kim, {Jung Seon} and Kim, {Seung Tae} and Park, {Kyong Hwa} and Choi, {In Keun} and Oh, {Sang Cheul} and Seo, {Jae Hong} and Shin, {Sang Won} and Kim, {Jun Suk} and Kim, {Yeul Hong}",
year = "2010",
month = "12",
day = "1",
doi = "10.1111/j.1743-7563.2010.01334.x",
language = "English",
volume = "6",
pages = "286--291",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma

AU - Kang, Eun Joo

AU - Choi, Yoon Ji

AU - Kim, Jung Seon

AU - Kim, Seung Tae

AU - Park, Kyong Hwa

AU - Choi, In Keun

AU - Oh, Sang Cheul

AU - Seo, Jae Hong

AU - Shin, Sang Won

AU - Kim, Jun Suk

AU - Kim, Yeul Hong

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Aim: There is no further treatment option for metastatic colon patients who are refractory to standard chemotherapy and to whom novel biological agents are not available. We evaluated the outcomes of mitomycin-C, 5-fluorouracil (5-FU) and leucovorin in patients with metastatic colon cancer previously treated with oxaliplatin/5-FU/leucovorin and irinotecan/5-FU/leucovorin.Methods: We retrospectively analyzed 46 patients who had received mitomycin-C/5FU/leucovorin between March 2008 and December 2009. All patients had failed prior first-line and second-line therapy containing oxaliplatin, irinotecan, and 5-FU.Results: The median age of the patients was 57.0 years (range, 34.0-76.0) and their median Eastern Cooperative Oncology Group performance status was 1 (0-2). A complete or partial response was not observed in any patient and stable disease was observed in 19 patients (41.3%). The median duration of follow up was 29 weeks (range 8-87 weeks). Median progression-free survival was 10 weeks (95% CI 8-12) and median overall survival was 38 weeks (95% CI 32-44). Grade 3 and 4 hematological toxicities included neutropenia in five patients (10.8%) and thrombocytopenia in four patients (8.8%). Grade 3 or 4 non-hematologic toxicities included nausea and vomiting in two patients. There were no treatment-related deaths.Conclusion: The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients.

AB - Aim: There is no further treatment option for metastatic colon patients who are refractory to standard chemotherapy and to whom novel biological agents are not available. We evaluated the outcomes of mitomycin-C, 5-fluorouracil (5-FU) and leucovorin in patients with metastatic colon cancer previously treated with oxaliplatin/5-FU/leucovorin and irinotecan/5-FU/leucovorin.Methods: We retrospectively analyzed 46 patients who had received mitomycin-C/5FU/leucovorin between March 2008 and December 2009. All patients had failed prior first-line and second-line therapy containing oxaliplatin, irinotecan, and 5-FU.Results: The median age of the patients was 57.0 years (range, 34.0-76.0) and their median Eastern Cooperative Oncology Group performance status was 1 (0-2). A complete or partial response was not observed in any patient and stable disease was observed in 19 patients (41.3%). The median duration of follow up was 29 weeks (range 8-87 weeks). Median progression-free survival was 10 weeks (95% CI 8-12) and median overall survival was 38 weeks (95% CI 32-44). Grade 3 and 4 hematological toxicities included neutropenia in five patients (10.8%) and thrombocytopenia in four patients (8.8%). Grade 3 or 4 non-hematologic toxicities included nausea and vomiting in two patients. There were no treatment-related deaths.Conclusion: The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients.

KW - 5-FU

KW - Leucovorin

KW - Mitomycin

KW - Refractory colon cancer

UR - http://www.scopus.com/inward/record.url?scp=78649783656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649783656&partnerID=8YFLogxK

U2 - 10.1111/j.1743-7563.2010.01334.x

DO - 10.1111/j.1743-7563.2010.01334.x

M3 - Article

C2 - 21114778

AN - SCOPUS:78649783656

VL - 6

SP - 286

EP - 291

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 4

ER -